Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

AstraZeneca Posts Positive Antibiotic Combo Results

August 19, 2014 11:30 am | News | Comments

AstraZeneca announced positive top-line results from RECLAIM-1 and RECLAIM-2, the pivotal Phase 3 studies investigating the potential of the antibiotic ceftazidime-avibactam as a treatment for hospitalized adult patients with complicated intra-abdominal infections. Read more...

TOPICS:

Unlocking the Power of Big Data in R&D, Part Two

August 19, 2014 11:23 am | by Sharon Benzeno, PhD, MBA, Senior Director, Business Development Bioinformatics, Elsevier | Articles | Comments

Big data is one of the hottest topics in R&D as its potential to accelerate successful drug development becomes more widely recognized. Part 2 of this two-part article analyses the new data-driven decision-making approaches make a difference to life science R&D. Read more...

TOPICS:

Breaking News: All Missing Ebola Patients Are Back

August 19, 2014 10:16 am | by Jonathan Paye-Layleh, John Heilprin, Associated Press | News | Comments

All the people who were being screened for Ebola when they fled a health center during looting are now back in a hospital, a Liberian official said Tuesda, but it is still not clear where the stolen bloody sheets and mattresses are. Read more...

TOPICS:
Advertisement

Small Molecules, Stem Cells Can Improve Hearing

August 18, 2014 3:14 pm | by Cynthia Fox, Science Editor | Articles | Comments

A scientist has found that a compound, LY-411575, can restore 20% of hearing in deaf mice, or ten decibels. Since electroacoustic hearing aids, at best, improve hearing by five decibels, there is a “good chance” the work will lead to help for deafened patients.

TOPICS:

HPV Vaccine Remains Effective After Eight Years, Study Says

August 18, 2014 2:39 pm | News | Comments

A new study examined whether the HPV vaccine remains effective 8 years after initial vaccination. The study followed boys and girls who were vaccinated with the HPV vaccine between the ages of 9 and 15. Read more...          

TOPICS:

Ruxolitinib Restores Hair in Alopecia Areata

August 18, 2014 2:28 pm | News | Comments

Researchers have identified the immune cells responsible for destroying hair follicles in people with alopecia areata, a common autoimmune disease that causes hair loss, and have tested an FDA-approved drug that eliminated these immune cells and restored hair growth in a small number of patients. Read more...

TOPICS:

FDA Approves Biogen's MS Drug Plegridy

August 18, 2014 2:06 pm | News | Comments

Biogen Idec said Friday that federal regulators have approved the specialty drugmaker's new treatment for people with relapsing forms of multiple sclerosis. Read more...                        

TOPICS:

CDC Scientist Kept Quiet About Flu Blunder

August 18, 2014 2:02 pm | by Mike Stobbe, AP Medical Writer | News | Comments

A government scientist kept silent about a potentially dangerous lab blunder and revealed it only after workers in another lab noticed something fishy, according to an internal investigation. Read more...              

TOPICS:
Advertisement

Allergan Names New CFO Amid Valeant Struggle

August 18, 2014 1:31 pm | News | Comments

Botox maker Allergan, which is fighting a hostile takeover bid from Valeant Pharmaceuticals, has named longtime executive Jim Hindman its new chief financial officer. Read more...                    

TOPICS:

UK Agrees to Re-Review Prostate Cancer Drug

August 18, 2014 11:16 am | News | Comments

Ferring Pharmaceuticals confirmed that, following an oral hearing in London, the panel upheld Ferring's appeal against the National Institute for Health and Care Excellence's final appraisal determination for the use of Firmagon as an option for treating advanced hormone-dependent prostate cancer. Read more...

TOPICS:

Daiichi Sankyo Kicks Off Etanercept Biosimilar Trial

August 18, 2014 11:11 am | News | Comments

Daiichi Sankyo Co. Ltd., in collaboration with the U.S. company Coherus BioSciences Inc., announced the start of the Phase 3 trial of CHS-0214, an investigational etanercept biosimilar, in rheumatoid arthritis (the RApsody trial) in Japan. Read more...

TOPICS:

Pfizer Submits NDA for Breast Cancer Drug

August 18, 2014 11:04 am | News | Comments

Pfizer Inc. announced it has completed the submission of a New Drug Application to the U.S. Food and Drug Administration for palbociclib in combination with letrozole for the treatment of postmenopausal women with ER+/HER2- breast cancer who have not received previous systemic treatment for advanced disease. Read more...

TOPICS:

Eisai Seeks Marketing Approvals for Anticancer Drug in Europe, U.S.

August 18, 2014 10:56 am | News | Comments

Eisai Co. Ltd. announced that it has submitted applications to regulatory authorities in the U.S. and Europe for marketing approval of its novel in-house developed anticancer agent lenvatinib mesylate as a treatment for progressive radioiodine-refractory differentiated thyroid cancer. Read more...

TOPICS:

Microchip Tracks Cancer Cell Migration

August 18, 2014 10:50 am | News | Comments

Using a microengineered device that acts as an obstacle course for cells that leaves just enough space for the cells to weave their way through, researchers have shed new light on a cellular metamorphosis thought to play a role in tumor cell invasion throughout the body. Read more...

TOPICS:

Ebola Quarantine Escapees Return

August 18, 2014 10:39 am | by Jonathan Paye-Layleh, Associated Press | News | Comments

Some of the people who fled an Ebola quarantine center in a Liberian slum when it was looted over the weekend are again under observation at a hospital Monday, as authorities struggle to contain the spread of an Ebola outbreak in West Africa. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading